Explore the vast range of titles available.

\"This book is about the history of emerging new therapies and preventions for a host of human diseases via biotechnology; the science that drives it and the people and companies who transformed that science into the biotechnologies we benefit from\"-- Provided by publisher.

Molecular profiling of single cells has advanced our knowledge of the molecular basis of development. However, current approaches mostly rely on dissociating cells from tissues, thereby losing the crucial spatial context of regulatory processes. Here, we apply an image-based single-cell transcriptomics method, sequential fluorescence in situ hybridization (seqFISH), to detect mRNAs for 387 target genes in tissue sections of mouse embryos at the 8–12 somite stage. By integrating spatial context and multiplexed transcriptional measurements with two single-cell transcriptome atlases, we characterize cell types across the embryo and demonstrate that spatially resolved expression of genes not profiled by seqFISH can be imputed. We use this high-resolution spatial map to characterize fundamental steps in the patterning of the midbrain–hindbrain boundary (MHB) and the developing gut tube. We uncover axes of cell differentiation that are not apparent from single-cell RNA-sequencing (scRNA-seq) data, such as early dorsal–ventral separation of esophageal and tracheal progenitor populations in the gut tube. Our method provides an approach for studying cell fate decisions in complex tissues and development. Improved integration of spatial and single-cell transcriptomic data provides insights into mouse development.

\"Preface This book started out as an interesting set of conversations with some very insightful and intelligent people. For twenty-five years, I've studied supply chains in almost every industry, including oil and gas, automotive, electronics, industrial production, and even financial services. And every time I met with executives, I met with the same statements: \"We're different-- you don't understand.\" But in the end, after spending enough time with these executives, it became clear that the same principles of supply chain management applied. Perhaps a different context, different terminology, but in the end, the same rules applied. When I started dabbling in healthcare, I originally encountered the same sets of objections. \"Healthcare is different,\" I would hear, \"After all, you have to consider the patient.\" But as I spent more and more time with healthcare executives, I only rarely heard the patient mentioned in the discussion. More often than not, the discussion focused on compliance, reimbursement, diagnosis-related groups (DRGs), and other terms that had very little to do with patient care. And as I studied the industry more, it became clear that organizations in the healthcare value chain, from the patient through hospitals, wholesalers, through insurance payers, manufacturers, and finally research and development (R&D), were not very well connected at all\"-- Provided by publisher.

In this book Andreas Dahlin has written a comprehensive and thorough review of plasmonic biosensors that operate by refractometric detection. After an introductory chapter on biosensors, in which he sets out the concepts of biosensing in its application to such areas as proteomics, medical diagnostics and environmental control, he undertakes an integrated coverage of surface chemistry, surface physics and optics, specifically related to the requirements of design of a plasmonic biosensor. Sections on nanoparticle plasmons and surface plasmons follow, leading to a review of SPR technology for biosensing. The optical properties of nanoholes in metal films and other more complicated plasmonic nanostructures are also briefly discussed. Later chapters discuss experimental plasmon spectroscopy and spectral analysis while the final sections discuss topics such as sensor response and the extent to which quantitative measurements can be made. The book introduces a few relatively controversial opinions on some open questions, such as how best to define sensor performance and the practical use of highly miniaturized sensors. Each of the chapters is extensively referenced and contains appropriate illustrations. The book contains a wealth of information that will be highly beneficial to both existing and new users of refractometric sensing techniques in life science research. It will be a valuable resource for post-graduate research students, academic researchers and those working in industry.

Cartilage repair and replacement is a major challenge in plastic reconstructive surgery. The development of a process capable of creating a patient-specific cartilage framework would be a major breakthrough. Here, we described methods for creating human cartilage in vivo and quantitatively assessing the proliferative capacity and cartilage-formation ability in mono- and co-cultures of human chondrocytes and human mesenchymal stem cells in a three-dimensional (3D)-bioprinted hydrogel scaffold. The 3D-bioprinted constructs (5 × 5 × 1.2 mm) were produced using nanofibrillated cellulose and alginate in combination with human chondrocytes and human mesenchymal stem cells using a 3D-extrusion bioprinter. Immediately following bioprinting, the constructs were implanted subcutaneously on the back of 48 nude mice and explanted after 30 and 60 days, respectively, for morphological and immunohistochemical examination. During explantation, the constructs were easy to handle, and the majority had retained their macroscopic grid appearance. Constructs consisting of human nasal chondrocytes showed good proliferation ability, with 17.2% of the surface areas covered with proliferating chondrocytes after 60 days. In constructs comprising a mixture of chondrocytes and stem cells, an additional proliferative effect was observed involving chondrocyte production of glycosaminoglycans and type 2 collagen. This clinically highly relevant study revealed 3D bioprinting as a promising technology for the creation of human cartilage.

Extracellular vesicles (EVs) in biofluids are heterogeneous in origin, surface protein expression, and biomolecular cargo. Isolation of specific EV subpopulations may enable studies of biomarkers originating from specific cell phenotypes and disease states. Acoustic trapping is a rapid, automatable EV isolation technique requiring minimal sample preprocessing; however, it lacks the specificity needed for some clinical studies. Combining acoustic trapping with immunoaffinity bead-based isolation could provide access to more specific EV content and broaden the applications of acoustic trapping. Here, we present a novel immuno-acoustic trapping methodology implemented on an automated platform with simple design. EVs were rapidly isolated (8 min) from ~ 17 µL blood plasma, generating two EV fractions from a single trapping run: acoustically trapped EVs and EVs bound specifically to anti-CD9 silica beads. We benchmark our technique against a manual (90 min) immunoaffinity isolation with multiple centrifugation washes. Nanoparticle tracking analysis and transmission electron microscopy with CD9 +  immunogold labeling confirmed isolation of intact EVs. Quantitative proteomic profiling showed that immuno-acoustic fractions contained proteins more strongly associated with CD9 than both acoustically and immunoaffinity-isolated fractions. This methodology can be adapted to isolate specific EV subpopulations expressing other surface proteins while simultaneously collecting a broad EV population as background reference.

This book tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team - denied their share of the profits - went and did it again. In this epic saga of money and science, a veteran financial journalist explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks - and make the people who find that rare molecule astonishingly rich. This book follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. The author's narrative immerses readers in the explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, this book illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine. -- Adapted from publisher's description.

Ambulatory oxygen therapy is prescribed for patients with chronic lung diseases who experience exertional hypoxemia. However, available devices may not adequately meet user requirements, and their performance characteristics are heterogeneous. This study aims to identify devices available for delivery of ambulatory oxygen therapy, the technologies that they use to generate oxygen, the performance characteristics of each device, and the development status. We used medical and engineering databases to identify peer-reviewed papers (eg, MEDLINE, IEEE). Gray literature was used to identify additional descriptions of ambulatory oxygen devices in military medicine, space exploration, or patents. The last search was conducted in September 2025. Documents that described a device that can deliver oxygen in an ambulatory context (defined as weighing less than 10 kg) and were written in English were included. Search results were screened for inclusion by 2 independent reviewers. Data were synthesized by descriptively mapping the performance of each product, the technology used, and the development status of emerging technologies. From 9702 records identified, a total of 166 met eligibility criteria (106 scientific publications and 60 gray literature). We identified 33 portable oxygen concentrators (POCs; 29 commercially available), 10 oxygen cylinders, and 6 portable liquid oxygen (LOX) devices. The POC products showed a trade-off between portability and oxygen delivery capacity (maximum flow rate ranging from 2.0 to 6.0 L/min; device weight ranging from 1.0 to 9.1 kg). Pressure swing adsorption with zeolite was the most common oxygen generation technology in POCs on the market. The mean maximum continuous operating time of POCs was 3.8 hours. Two prototype POCs (maximum flow rate of 4-6 L/min and device weight of 8-9 kg) were developed for space exploration using modified adsorbents. LOX devices were the lightest and had the longest continuous operating time. Innovations in delivery included the downsizing of a POC by using nanozeolite as an adsorbent and pulse oximeter oxygen saturation (SpO )-targeted automatic titration of oxygen delivery based on the user's SpO . This scoping review is the first study to integrate medical, engineering, and gray literature on ambulatory oxygen devices and their development. Although prior literature has narratively explained the products and technologies, no previous research has systematically investigated them. This review showed that POCs available to consumers may not meet the needs of patients in terms of flow rate, portability, and operating time. LOX devices offered superior performance but are limited by high costs. Limitations of this review include the difficulty of comparing product performance across oxygen delivery settings and that the records were largely obtained from English-language sources. Innovation in ambulatory oxygen technology has been limited over the past decade, highlighting urgent need for research and development of new lightweight devices with higher oxygen delivery. OSF Registries 10.17605/OSF.IO/QS7FX; https://osf.io/qs7fx.